Evidence map›Paper›PMID 31902910›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.

Yoko Fujita, Maho Terashita, Masahiko Yazawa, Yukitaka Yamasaki, Tomonori Imamura, Junichiro Kibayashi, Toshihiro Sawai, Yoshihiko Hidaka, Katsuki Ohtani, Norimitsu Inoue and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yoko FujitaDivision of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.
Maho TerashitaDivision of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.
Masahiko YazawaDivision of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.
Yukitaka YamasakiDepartment of Infectious Disease, St. Marianna University School of Medicine, Japan.
Tomonori ImamuraDepartment of Emergency and Critical Care Medicine, Tokyo Metropolitan Police Hospital, Japan.
Junichiro KibayashiDepartment of Obstetrics and Gynecology, Yokohama General Hospital, Japan.
Toshihiro SawaiDepartment of Pediatrics, Shiga University of Medical Science, Japan.
Yoshihiko HidakaDepartment of Molecular Genetics, Wakayama Medical University, Japan.
Katsuki OhtaniThe Japanese Association for Complement Research, Japan.
Norimitsu InoueDepartment of Molecular Genetics, Wakayama Medical University, Japan.
Yugo ShibagakiDivision of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Japan.
St. Marianna University School of Medicine · JPWakayama Medical University · JPRakuno Gakuen University · JPShiga University of Medical Science · JPTokyo Metropolitan Police Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical hemolytic uremic syndrome (aHUS) is an extremely rare condition caused by an excessive activation of the complement pathway based on genetic or acquired dysfunctions in complement regulation, leading to thrombotic microangiopathy (TMA). A complement-amplifying condition (CAC) can trigger aHUS occurrence along with complement abnormality. We herein report a case of severe TMA after laparoscopic myomectomy in a healthy woman. This case was eventually diagnosed as complement-mediated TMA secondary to surgical invasive stress as a CAC, with no definitive diagnosis of aHUS despite a genetic test. The patient fully recovered after several eculizumab administrations.

Indexed as

AdultAntibodies, Monoclonal, HumanizedComplement Inactivating AgentsFemaleHumansLaparoscopyPostoperative HemorrhageRare DiseasesThrombotic MicroangiopathiesUterine MyomectomyAntibodies, Monoclonal, HumanizedComplement Inactivating AgentseculizumabaHUSatypical hemolytic uremic syndromecomplement amplifying conditioneculizumabthrombotic microangiopathyTMA

Identifiers

PMID31902910
PMCPMC6995713
OpenAlexW2997675070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.